Hair / health / critical readingA thread between questions and evidence
Calvizie / CapelliThe thread of evidence
The journal / guide

Androgenetic alopecia: understanding hair thinning

Androgenetic alopecia involves progressive follicle miniaturisation. It can affect men and women; the distribution of thinning is part of an examination, rather than a test to interpret yourself.

Updated 15 October 2026Editorial source check · no individual clinical review claimed
ATLAS / 01 · A sequence, not a stopwatch

Every strand
has its own rhythm.

RENEWAL↻

Simplified, not to scale. Follicles are not all in the same phase; this drawing does not measure timing, quantities or your condition. Source: DermNet · Hair shedding ↗

What miniaturisation means

Genetic susceptibility and hormonal factors contribute to changes in affected follicles: the hairs they produce can become progressively finer. Family history is worth mentioning, but a relative’s experience cannot predict your own course precisely.

An online photo comparison cannot confirm the cause of thinning either. A dermatologist considers your history, the distribution of changes and the scalp, and checks whether anything else needs investigating. Increased shedding at the same time may have another explanation.

Define a practical goal

It helps to distinguish slowing a change, achieving a possible improvement and changing how your hair looks. These are different goals. Ask which is realistic for you and how it will be assessed over time.

Options may include medicines, cosmetic camouflage or, where appropriate, a surgical assessment. No option should be presented as compulsory or as a guarantee of your original density. Distress and personal preferences also deserve a place in the decision.

Questions that help you choose

  • Which findings support this diagnosis?
  • What benefit is reasonable to expect, and when should we review it?
  • What risks and commitments come with each option?
  • What happens if treatment is stopped?

For a medicine, its active ingredient and route of administration do not describe every condition of use. Check the approved information for the specific product. This guide supports that conversation without providing doses or selecting a personal treatment.

Web editorial team · 2026 edition

Original text prepared with automated writing assistance and reference checks. No individual clinical reviewer is attributed to this guide.

Methods, limitations and corrections ↗

Sources and limitations

  1. Male pattern hair loss (androgenetic alopecia)British Association of Dermatologists / British Hair and Nail Society · Document: 2024-06 · Editorial check: 15 October 2026Next review scheduled for June 2027. UK licensing and NHS information do not automatically apply to Italy; read finasteride safety alongside AIFA’s 2025 notice.
  2. Hair loss: diagnosis and treatmentAmerican Academy of Dermatology · Document: date not stated · Editorial check: 15 October 2026Used for the general clinical pathway. FDA approvals and US insurance information do not describe Italy.
  3. Summary of product characteristics and patient information leafletAIFA · Document: date not stated · Editorial check: 15 October 2026A methodological page; it does not verify the current SmPC of every medicine.